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With increasing clinical emergence of multidrug-resistant Gram-negative pathogens and the paucity of
new agents to combat these infections, colistin (administered as its inactive prodrug colistin methane-
sulfonate [CMS]) has reemerged as a treatment option, especially for critically ill patients. There has been
a dearth of pharmacokinetic (PK) data available to guide dosing in critically ill patients, including those
on renal replacement therapy. In an ongoing study to develop a population PK model for CMS and
colistin, 105 patients have been studied to date; these included 12 patients on hemodialysis and 4 on
continuous renal replacement therapy. For patients not on renal replacement, there was a wide variance
in creatinine clearance, ranging from 3 to 169 ml/min/1.73 m2. Each patient was treated with a physician-
selected CMS dosage regimen, and 8 blood samples for PK analysis were collected across a dosage interval
on day 3 or 4 of therapy. A linear PK model with two compartments for CMS and one compartment for
formed colistin best described the data. Covariates included creatinine clearance on the total clearance of
CMS and colistin, as well as body weight on the central volume of CMS. Model-fitted parameter estimates
were used to derive suggested loading and maintenance dosing regimens for various categories of patients,
including those on hemodialysis and continuous renal replacement. Based on our current understanding
of colistin PK and pharmacodynamic relationships, colistin may best be used as part of a highly active
combination, especially for patients with moderate to good renal function and/or for organisms with MICs
of >1.0 mg/liter.
There has been an increasing clinical emergence of mul-
tidrug-resistant (MDR) Gram-negative pathogens, in par-
ticular Pseudomonas aeruginosa, Acinetobacter baumannii,
and Klebsiella pneumoniae, and this is especially of concern
for critically ill patients (19, 30). Infections caused by these
organisms are increasingly difficult to treat due to a wide
variety of resistance mechanisms. With a paucity of new
drugs available to treat infections caused by these MDR
organisms, colistin, also known as polymyxin E, which was
first introduced in the late 1950s, has reemerged as a treat-
ment of choice and often as the only antibiotic active against
these organisms (14, 26, 33). Colistin is available for paren-
teral administration as colistin methanesulfonate (CMS), an
inactive prodrug that is less nephrotoxic than colistin (7, 25).
Because it has been more than 50 years since CMS became
available for clinical use, it has never been subjected to
contemporary drug development procedures. As a result,
there are very limited pharmacokinetic (PK) data available
to guide appropriate CMS dosage selection, especially in
critically ill patients. Early studies, including those used for
current product labeling, utilized nonspecific microbiologi-
cal assays which are not able to differentiate colistin present
in biological samples at the time of collection from that
formed from CMS in vitro during the incubation phase of
microbiological assays. Current dosing guidelines therefore
are not scientifically based, have been found to be inappro-
priate, and have led to treatment failure as well as emer-
gence of resistance (1, 6, 20).
The need to administer antibiotics in critically ill patients
based upon PK, pharmacodynamic (PD), and toxicodynamic
(TD) principles in order to optimize the benefit and mini-
mize the potential for development of resistance has been
highlighted recently (30). The relatively recent development
of separate assays for colistin and CMS in biological fluids
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(17, 21–22, 32) has provided some insight into the disposi-
tion of CMS and formed colistin in small populations of
critically ill patients (total of 32) with near-normal renal
function (29, 31). The removal of CMS and colistin by con-
tinuous renal replacement therapy and intermittent hemo-
dialysis has been assessed in just three critically ill patients
(27–28). As a result, there is a major paucity of information
on the disposition of the prodrug CMS and formed colistin
in critically ill patients across a wide range of renal function.
The aims of this study were to develop a population PK
model for CMS and colistin in a larger population of criti-
cally ill patients with a wider range of renal function more
typical of this population, including those receiving renal
replacement therapy. This would permit characterization of
the patient covariates influencing the disposition of CMS
and formed colistin and, by integrating the PK results with
literature PD data, development of improved dosing guide-
lines for use in this difficult-to-treat population. This report
presents the results for 105 critically ill patients from an
ongoing study that will recruit a total of 238 patients to
define the population PK/PD/TD of CMS and formed colis-
tin. The interim dosing suggestions contained herein pro-
vide important information for clinicians to assist in the use
of intravenous CMS/colistin in this difficult-to-manage pop-
ulation.
MATERIALS AND METHODS
Patients and study design. This was an open-label population PK study
conducted at two sites in the United States and one in Thailand. Patients were
eligible for enrollment in the study if they were 18 years old, receiving CMS
as part of their clinical care for treatment of bloodstream infection or pneu-
monia due to a Gram-negative bacillus lacking susceptibility to all of the
antibiotics cefepime or ceftazidime, imipenem or meropenem, piperacillin-
tazobactam, and ciprofloxacin or levofloxacin, and had adequate venous ac-
cess to enable collection of blood for determination of CMS and formed
colistin in plasma. Patients who were pregnant or breastfeeding, were con-
comitantly receiving CMS/colistin or polymyxin B delivered directly into the
respiratory tract, or had cystic fibrosis were excluded. Data collected included
demographic information, APACHE II (acute physiology and chronic health
evaluation II) scores, serum creatinine, comorbidities, use of immunosup-
pressives, and presence and type of renal replacement (intermittent hemo-
dialysis [HD] or continuous renal replacement therapy [CRRT]). Informed
consent was obtained for all patients, and the study was approved by the
ethics committee of each institution.
CMS administration. CMS (Colistate [Atlantic Pharmaceutical Co., Bang-
kok, Thailand], and colistimethate for injection [Paddock Laboratories, Inc.,
MN and X-Gen Pharmaceuticals, Inc., Big Flats, NY]) was administered
intravenously as a short-term infusion (range of infusion durations, 9 to 180
min) every 8 to 24 h according to a dosage regimen determined by the
respective treating physician. The dose of CMS was expressed as colistin base
activity (CBA); 150 mg CBA is equivalent to approximately 5 million units
(MU) of CMS (26) and approximately 400 mg CMS sodium.
Pharmacokinetic sampling. Eight samples of blood (each 3 ml) were col-
lected across a dosage interval on day 3 to 4 of CMS therapy. Samples were
collected immediately prior to a dose, at the end of the CMS infusion, and at
the following nominal times thereafter: 0.5, 1, 2, 4, 8, and 12 h or immediately
prior to the next dose if CMS was not being administered every 12 h. The
actual times of CMS administration and blood sampling were recorded.
Samples were collected in heparinized blood collection tubes, placed on ice,
and centrifuged at 4°C within 1 h of collection. The resulting plasma was
stored at 70 to 80°C to prevent in vitro conversion of CMS to colistin (11).
For patients on either HD or CRRT, the total volume of dialysate collected
across a collection interval was measured or calculated from known flow
rates. For subjects on HD, “spot” samples of dialysate were collected just
after the start of the dialysis session, once every hour during dialysis, and just
prior to the end of the session (typically, 4 such samples were collected);
blood samples were also collected at the start and end of the session in those
cases where the HD occurred on a different day from that for the collection
of the eight blood samples mentioned above. For subjects on CRRT, “spot”
dialysate samples (approximately 8) were collected at the same nominal times
as for the eight interdosing blood samples described above.
Determination of CMS and colistin concentrations in plasma. CMS and
colistin concentrations in plasma were quantified by previously reported
high-performance liquid chromatographic methods (21–22). Plasma CMS
and colistin concentrations were quantified within 4 months of collection to
avoid in vitro conversion of CMS to colistin (11). The accuracies of the plasma
colistin assay at the low, medium, and high quality control concentrations
were 106%, 100%, and 103% of target concentrations, respectively, with
corresponding precision (CV) of 6.27%, 7.85%, and 6.48%. The respective
values for the low, medium, and high quality control concentrations for CMS
were accuracies of 103%, 99%, and 98% with precision of 11.8%, 6.65%, and
6.46%. The limits of quantification were 0.10 mg/liter for colistin and 0.30
mg/liter for CMS.
Pharmacometric methods. A nonlinear mixed-effects modeling tool,
S-ADAPT (Monte Carlo parametric expectation maximization [MCPEM]),
was used to analyze the plasma concentration-versus-time data for both CMS
and formed colistin (3, 8). One-, two-, and three-compartment models were
explored for the plasma concentration-time profiles for CMS and colistin,
with linear or nonlinear (saturable) elimination. The model was built in a
piecewise manner; first the model for CMS was developed, after which colis-
tin data were included and the model characterizing colistin disposition was
built. These models were first fit to the data for patients not on renal
replacement. Subsequently, the “best-fit” model was fit to the data for pa-
tients on HD and CRRT by including an extracorporeal clearance which
played a role in the plasma disposition of CMS and colistin. Attempts to
comodel the plasma and dialysate data in patients on renal replacement were
not successful. The comodeled fits were inferior for some patients (compared
with those from modeling of plasma data only), probably due to the propor-
tion of dialysate concentrations that were below the limit of quantification.
Subsequently, the extracorporeal clearances of CMS and colistin were mod-
eled based upon plasma concentration data only. Additional modifications to
this model were evaluated. These modifications included the presence or
absence of transit compartments to characterize a decrease in plasma con-
centrations of CMS and the slow rise in plasma concentrations of colistin for
subjects with renal failure. As a final step, the models for subjects on renal
replacement and those not on renal replacement were combined and comod-
eled to allow for maximal benefit of population PK. Residual error models
evaluated were proportional or additive plus proportional. The interindi-
vidual variability was assumed to be log-normally distributed. Plasma con-
centrations below the limit of quantification were handled by the Beal M3
method (5).
Covariate model building was performed using forward selection and back-
ward deletion. Candidate covariates that were evaluated for their possible
effect on CMS and colistin disposition included the following: body size
(actual and ideal weight, body surface area [BSA], body mass index [BMI]),
gender, age, creatinine clearance (CrCL), and APACHE II score on clear-
ance; and body size (actual and ideal weight, BSA, BMI) on volume of
distribution. Calculation of CrCL was done by use of the Jelliffe equation (18)
for patients with unstable renal function. Model evaluation was performed via
nonparametric bootstrap techniques using 500 randomly sampled data sets.
Each new data set contained the same proportion of patients on HD or on
CRRT as the original data set. After building the population PK model for
CMS and colistin, we applied it to the development of suggestions for both
loading and maintenance doses of CMS designed to achieve a desired target
plasma colistin concentration. First, each individual’s fitted PK parameter
estimates from the final population PK model were used to compute that
subject’s ideal loading and maintenance doses to achieve a user-specified
target plasma colistin concentration. Any and all covariates for CMS and
colistin PK which were also significantly related to the ideal dose were
incorporated into the dosing algorithms. Further detail is provided in Results.
RESULTS
Patient characteristics. A total of 105 patients studied to
date (recruited between February 2009 and July 2010) were
included in this study, of whom 12 were receiving HD and 4
were on CRRT (3 on continuous veno-venous hemodialysis
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[CVVHD] and 1 on continuous veno-venous hemofiltration
[CVVH]). Patient characteristics are summarized in Table
1. The HD patients had dialysate flow rates ranging from
500 to 600 ml/min, blood flow rates ranging from 200 to 350
ml/min, membrane surface areas ranging from 1.5 to 1.9 m2,
and membrane type SF190E, Rex 18, or SF150; the fre-
quency of HD ranged from daily to twice weekly, and ses-
sion duration was 3 h 15 min to 4 h 15 min (median, 4 h). All
3 CVVHD patients had dialysate flow rates of 42 ml/min,
blood flow rates of 150 ml/min, membrane surface area of
0.9 m2, and membrane type ANG9HF. The median daily
dose of colistin base activity across the 105 patients was 200
mg (range, 75 to 410 mg).
Plasma concentrations of CMS and colistin. A total of 851
plasma samples were available for each of CMS and colistin;
no samples were excluded from the modeling analyses.
Plasma concentration-time profiles of CMS and formed
colistin for all patients are presented in Fig. 1. For each
patient, the profile for formed colistin was much flatter than
that for CMS, consistent with the active antibacterial having
a longer terminal half-life than the prodrug. There was
substantial interpatient variability in the plasma concentra-
tions of both CMS and colistin achieved from the empiri-
cally selected CMS dosage regimens. The area under
the plasma concentration-versus-time curve over a day
(AUC0–24) for formed colistin ranged from 11.5 to 225
mg  h/liter. Division of each AUC0–24 value by 24 h gener-
ates the average steady-state plasma concentration (Css,avg)
of colistin for each patient; the range of the colistin Css,avg
across all patients was 0.48 to 9.38 mg/liter (median, 2.36
mg/liter). There was a strong inverse trend between the
colistin Css,avg and the CrCL (Fig. 2); the corresponding
relationship between the physician-selected daily dose of
CBA and CrCL is shown in the same figure.
Population PK analysis. The disposition of CMS and
formed colistin was best described by a linear model com-
prising two and one compartments, respectively. Equations
1 to 3 below represent the differential equations for the
disposition of CMS and colistin. CMSc is the mass of CMS
in the central compartment, CMSp is the mass of CMS in
the peripheral compartment, and “colistin” in equation 3 is
the mass of colistin in the single compartment for colistin.
V1 and V2 represent the central and peripheral volumes for
CMS, and V3 represents the volume of distribution for colis-
tin. R(1) represents the infusion rate of CMS, and CLD1
represents the distributional clearance between the central
and peripheral compartments for CMS. CLTCMS and CLTC
refer to the total intrinsic clearance for CMS and colistin.
CLTCMS was modeled as the sum of renal clearance and a
nonrenal clearance (CLNRCMS), with a portion of the latter
TABLE 1. Patient characteristics
Characteristic Value
Median (range)
Age (yr) ................................................................... 71 (19–92)
Wt (kg) .................................................................... 59.1 (30.0–106.4)
Height (cm).............................................................162.0 (140.0–184.5)
APACHE II score.................................................. 21 (4–38)
Serum creatinine (mg/dl) ...................................... 1.2 (0.2–10.3)
Creatinine clearance (ml/min/1.73 m2)................ 28.7 (0–169)
No. (%) of patients
Sex
Male ..................................................................... 68 (64.8)
Female ................................................................. 37 (35.2)
With comorbidity
Diabetes............................................................... 24 (22.9)
Malignancy .......................................................... 22 (21.0)
Immunosuppression ........................................... 13 (12.4)
Hepatic failure.................................................... 10 (9.5)
With infection treated with CMS
Bacteremia .......................................................... 11 (10.5)
Pneumonia .......................................................... 94 (89.5)
With source of bacteremia
Pneumonia .......................................................... 1 (9.1)
Intra-abdominal .................................................. 5 (45.5)
Urinary tract infection....................................... 2 (18.2)
Unknown ............................................................. 3 (27.3)
With renal replacement therapy
Hemodialysis ....................................................... 12 (11.4)
Continuous renal replacement ......................... 4 (3.8)
FIG. 1. Steady-state plasma concentration-time profiles of the prodrug CMS (A) or formed colistin (B) in 105 critically ill patients (89 not on
renal replacement, 12 on intermittent HD, and 4 on CRRT). The physician-selected daily doses of colistin base activity (CBA) ranged from 75 to
410 mg/day; the dosage intervals ranged from 8 to 24 h, and hence the interdosing blood sampling interval spanned the same range.
3286 GARONZIK ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 N
ovem
ber 5, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
forming colistin. Colistin clearance and volume of distribu-
tion (V3) are thus conditioned on the unknown fraction (fm)
of the nonrenal clearance of CMS that actually forms colis-
tin (this fm is not the fraction of the total administered dose
of CMS converted to colistin). For patients on hemodialysis,
HD clearance for CMS (CLHDCMS) and colistin (CLHDC)
also played a role in the disposition of CMS and colistin.
These clearance values were estimated during dialysis and
set to zero when dialysis was turned off. Similarly, for pa-
tients on CRRT, CLRRTCMS and CLRRTC played a role in
the disposition of CMS and colistin.
dCMSc
dt  R1 CLD1 CMScV1  CMSpV2 
 CLTCMS  CLHDCMS  CLRRTCMS
CMSc
V1
(1)
dCMSp
dt  CLD1 CMScV1  CMSpV2  (2)
dColistin
dt  CLNRCMS
CMSc
V1
 CLTC  CLHDC  CLRRTC
Colistin
V3 (3)
In order to inform the model and constrain clearance due to
CRRT to be smaller than clearance due to dialysis in HD
patients, clearances of CMS and colistin due to CRRT were
modeled as a fraction (FRRT) of the respective clearances due
to dialysis in HD patients. The equations below define the
clearances due to CRRT.
CLRRTCMS  CLHDCMS  FRRT (4)
CLRRTC  CLHDC  FRRT (5)
A thorough PK covariate analysis was performed for candidate
covariates (both as fixed and random effects where appropri-
ate). Total CMS clearance (CLTCMS) was modeled as a func-
tion of CrCL and two random effects, CLRSLOPE and
CLNRCMS, using equation 6 below.
CLTCMS  CrCL  CLRSLOPE  CLNRCMS (6)
The central compartment volume for CMS (V1) was modeled
as a function of weight (fixed effect) and centered using a value
approximating the median weight, 60.0 kg, using equation 7
below. V1POP is a standard “population” volume of distribution
value (liters/60 kg) for the central volume of CMS, which was
allowed to vary as a function of body weight.
V1 V1pop WTKG60.0  (7)
The apparent colistin clearance (CLTC/fm) was modeled
as a sum of two fixed effects, a renally dependent component
(CLRCSL_POP) and a nonrenally dependent component
(CLNRC_POP), using equation 8 below.
CLTC  CrCL  CLRCSL_POP  CLNRC_POP (8)
The derived terminal half-lives for CMS and colistin in patients
not on CRRT were also dependent on CrCL: for 20 patients
with CrCL of10 ml/min/1.73 m2, the median half-life (10th to
90th percentile) for CMS was 11 (6.3 to 43) h and that for
colistin was 13 (7.0 to 18) h; for 62 patients with CrCL of 11 to
69 ml/min/1.73 m2, the half-life for CMS was 5.6 (3.2 to 14) h
and that for colistin was 13 (8.2 to 19) h; for 19 patients with
CrCL of70 ml/min/1.73 m2, the half-life for CMS was 4.6 (1.9
to 9.1) h and that for colistin was 9.1 (6.3 to 12) h.
All model-fitted parameters were estimated with good to
excellent precision (standard errors between 3.1 and 44%),
with core parameters having moderate interindividual variabil-
ity (23 to 70%) (Table 2). Representative individual fits are
presented in Fig. 3. The overall goodness-of-fit plots (observed
FIG. 2. Relationship of physician-selected daily dose of colistin base activity (CBA) (A) and the resultant average steady-state plasma colistin
concentration (B) with creatinine clearance in 105 critically ill patients.
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versus fitted concentrations) for both CMS and colistin indi-
cated that the individual fits were precise and unbiased, with r2
values of 0.94 for both CMS and colistin (data not shown).
The results of the bootstrap analysis (Table 2) agreed well with
the final model estimates (for parameters not relating to renal
replacement), with the median value from the bootstrap runs
being within 1 to 3% of the final estimate, with a 10 to 90%
confidence interval (CI) for all parameter means (except
CLRCSL_POP/fm) no more than 22.3% below or 24.6% above
the final model estimate. Similar precision was also noted for
the variance (not shown) around the estimates, with the me-
dian value from the bootstrap being within 1 to 6% of the final
model-fitted estimate with a 10 to 90% CI no more than 48.2%
above or 48.5% below the fitted value.
Development of CMS dose suggestions for various catego-
ries of patients. The population PK models for patients not on
renal replacement and those receiving HD or CRRT were then
used to derive maintenance dosing suggestions for CMS in
critically ill patients to achieve a desired “target” Css,avg of
colistin in plasma.
For those patients not on renal replacement (n  89) to-
gether with those receiving HD (n 12), each patient’s “ideal”
maintenance dose of CMS (expressed as CBA) was computed,
based on their individual fitted PK parameter estimates from
the population PK model and a chosen target plasma colistin
Css,avg. The “ideal” maintenance dose of CBA required to
achieve each 1.0 mg/liter of target colistin Css,avg for each
patient was then regressed against the corresponding CrCL,
adjusted by differentially weighing the cost of being above
TABLE 2. Population PK model-fitted parametersa
Category Parameter (units)
Model-fitted result Bootstrap resultc
No. of
subjects Estimate % SE % IIV Median
10th
percentile
90th
percentile
CMS V1 (liters) 105 11.5 32 102 93.9 113
V2 (liters) 105 18.7 9.0 79 99.4 85.6 124
CLD1 (liters/h) 105 7.98 12 84 97.0 77.8 117
Random effects CLRSLOPE (liters/h/CrCL) 89 0.0613 8.8 70 99.5 88.1 113
CLNRCMS (liters/h) 105 1.90 5.6 36 101 93.6 111
Colistin V3/fm (liters) 105 45.1 6.1 48 102 90.1 116
CLTC/fm (liters/h) 105 2.72 23 100 92.0 110
Fixed effects CLRCSL_POP/fm (liters/h/
CrCL)
89 0.0147 28 102 68.0 142
CLNRC/fm (liters/h) 105 2.19 5.8 99.1 92.7 107
V1POP (liters/60 kg) 105 11.9 5.1 103 94.1 113
Renal
replacementb
CLHDCMS (liters/h) 16 5.69 44 96
CLHDC (liters/h) 16 3.40 3.1 15
CLRRTCMS (liters/h) 4 3.85 12 24
CLRRTC (liters/h) 4 2.06 18 37
Error variance SDSLOPE_CMS 105 0.183 4.8 98.3 87.4 111
SDSLOPE_C 105 0.099 4.1 99.0 85.8 114
SDINTERCEPT 105 Fixed at
LOQ
Fixed at
LOQ
Fixed at
LOQ
a Estimates refer to the geometric mean of the estimates in the population. This may refer to the entire 105 subjects, 89 subjects not on any renal replacement, 16
subjects on some form of renal replacement, or 4 subjects on CRRT and is specified by the “No. of subjects” column. % SE refers to the standard error or the precision
of the estimates, while % IIV refers to the interindividual variability in the population. LOQ refers to the limit of quantification.
b For the two RRT groups, the geometric mean, % SE, and % IIV are based on summary statistics of the post hoc estimates in the indicated population.
c Bootstrap results are expressed as a % of the model-fitted estimates.
FIG. 3. Representative individual population PK model fits of
CMS (A, C, and E) or formed colistin (B, D, and F) in critically ill
patients. Panels A and B are representative of a subject not on renal
replacement, C and D are representative of a subject on HD, and E
and F are representative of a subject on CRRT.
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(increased likelihood of toxicity) and below (subtherapeutic
concentrations, thus decreasing the likelihood of efficacy) the
target (4). We accomplished this by minimizing a weighted
least-squares cost function. For weighting, we defined a desir-
able window and made the judgment to consider missing the
window “high” (with a risk of toxicity) as one-half the cost
(weight) of missing it “low” (with a risk for treatment failure).
The final weighted regression maximized the cases within the
desired window and minimized the resulting cost function (bal-
ancing the risks of being below versus being above the window,
favoring the latter by approximately 2:1). The resultant rela-
tionship (Fig. 4) forms the basis of a maintenance dosing al-
gorithm for critically ill patients in the two above-mentioned
categories (Table 3, equation 10). It should be noted that the
“ideal” maintenance dose of CBA required to achieve each 1.0
mg/liter of colistin target Css,avg for each of the 12 HD patients
ranged from 23 to 41 mg CBA per day (median, 30 mg CBA
per day). This median accords well with the daily maintenance
dose of CBA calculated using equation 10 (Table 3) in a
patient with a CrCL of zero.
Our population PK modeling in the present study (Table 2)
and previous findings (15, 28) indicate that both CMS and
colistin are efficiently cleared by hemodialysis. In order to
replace CMS and colistin lost due to hemodialysis and main-
tain a colistin Css,avg on an HD day similar to that on a non-HD
day, the fitted clearances due to HD for each of CMS and
colistin were used to determine the magnitude of a CMS sup-
plemental dose. A higher supplemental dose of CMS is re-
quired if it is administered during the last hour of the HD
session compared with administration after the end of the HD
session (Table 3). It was assumed that the HD session occurs
toward the end of a CMS maintenance dosage interval. The
“ideal” maintenance doses computed from the population PK
model for 4 patients on CRRT (3 CVVHD and 1 CVVH)
ranged from 112 to 260 (median, 192) mg CBA/day per 1.0
mg/liter colistin target Css,avg, leading to the suggested daily
FIG. 4. Relationship between the “ideal” maintenance dose of
CMS (expressed as mg per day of colistin base activity [CBA] per each
1.0 mg/liter of colistin Css,avg target) and creatinine clearance in 101
critically ill patients (89 not on renal replacement and 12 on HD).
TABLE 3. Suggested loading dose and daily maintenance doses of CMSa
Dose Category of critically ill patient Dosing suggestions
Loading dose All patient categories Equation 9:
Loading dose of CBA (mg)  colistin Css,avg target
b  2.0  body wt (kg).c See
caveat in footnote c. First maintenance dose should be given 24 h later.
Maintenance dose Not on renal replacement Equation 10:
Daily dose of CBA (mg)  colistin Css,avg target
b  (1.50  CrCL  30).d
Recommended dosage intervals based on CrCL: 10 ml/min/1.73 m2, every
12 h, 10-70 ml/min/1.73 m2 every 12 (or 8) h, and 70 ml/min/1.73 m2 every
12 (or 8) h. See important caveat in footnote d.
Receiving intermittent hemodialysis Daily dose of CBA on a non-HD day to achieve each 1.0-mg/liter colistin Css,avg
targetb  30 mge.
Supplemental dose of CBA on a HD dayf: add 50% to the daily maintenance
dose if the supplemental dose is administered during the last hour of the HD
session, or add 30% to the daily maintenance dose if the supplemental dose
is administered after the HD session. Twice-daily dosing is suggested.
Receiving continuous renal replacement Daily dose of CBA to achieve each 1.0-mg/liter colistin Css,avg target  192 mg.
g
Doses may be given every 8-12 h.
a Expressed as mg of colistin base activity (CBA) for various categories of critically ill patients. The suggested maintenance daily dose would commence 24 h after
administration of a CMS loading dose. Example: To target a colistin Css,avg of 2.5 mg/liter, a 55-kg patient with a CrCL of 40 ml/min/1.73 m2 would receive a loading
dose of 275 mg CBA followed in 24 h by commencement of a maintenance regimen of 225 mg CBA/day in 2 to 3 equally divided doses.
b Colistin Css,avg target is expressed in mg/liter. This target should be based on MIC, site, and severity of infection.
c Use the lower of ideal or actual body weight, expressed in kg. At this time, we suggest caution in the use of a loading dose greater than 300 mg CBA (see the text
for more details).
d Based upon the population PK analysis for 101 critically ill patients not on continuous renal replacement therapy. Colistin Css,avg target expressed in mg/L.
Creatinine clearance (CrCL) expressed in ml/min/1.73 m2. Although the Jelliffe equation was used to estimate CrCL in this study, other means (e.g., Cockcroft and
Gault equation) may be used to estimate CrCL which would then be normalized to a body surface area of 1.73 m2. See text for caveat regarding use of the algorithm
in patients with CrCL values  70 ml/min/1.73 m2 or when targeting a “high” colistin Css,avg, both being circumstances where the algorithm may predict daily doses
of CBA substantially greater than the current upper limit in the product label.
e Based upon use of equation 10 and setting CrCL to zero.
f Supplemental dose of CMS to achieve a similar colistin Css,avg on a HD day as occurs on a non-HD day. It is assumed that the hemodialysis session occurs toward
the end of a CMS dosage interval.
g Based on the population PK analysis for 4 critically ill patients receiving continuous renal replacement therapy.
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maintenance dose of CBA listed in Table 3. The suggested
dose intervals are dependent on CrCL; see Table 3.
The maintenance dosing suggestions for various categories
of critically ill patients (Table 3) were then applied to all
patients studied to date, using a colistin Css,avg target of 2.5
mg/liter, corresponding to a steady-state colistin AUC0–24 of 60
mg  h/liter; the colistin Css,avg target of 2.5 mg/liter was very
similar to the median Css,avg of 2.36 mg/liter achieved in the
105 patients with the physician-selected maintenance doses of
CMS, but the predicted variances were substantially lower.
Among those not on any renal replacement plus those on HD,
3/101 (	3%) of patients are predicted to have achieved a
colistin Css,avg of 0.5 to 1 mg/liter, 86/101 (	85%) a colistin
Css,avg of 1.0 to 4.0 mg/liter, and 12/101 (	12%) a colistin
Css,avg of 4.0 mg/liter. Among those on HD, all 12 patients
would have been predicted to achieve a colistin Css,avg between
1.9 and 3.4 mg/liter. Patients on CRRT required a mainte-
nance dose 	6-fold higher than that required by an HD pa-
tient on a nondialysis day. With a dose of 480 mg CBA per day,
aiming to achieve a colistin Css,avg of 2.5 mg/liter, all 4 CRRT
patients would be predicted to achieve Css,avg concentrations of
colistin between 1.9 and 4.2 mg/liter.
The predicted steady-state colistin AUC0–24 values, from the
above algorithm-predicted maintenance doses applied back to
all 105 patients, were then linked with PD models for 3 strains
of A. baumannii (MICs of 0.5, 1.0, and 1.0 mg/liter) and 3
strains of P. aeruginosa (MICs of 0.5, 1.0, and 1.0 mg/liter)
previously studied using neutropenic mouse thigh and lung
infection models (12–13). In both murine models, the most
predictive PK/PD index for antibacterial effect of colistin
against both species was the ratio of AUC0–24 [unbound] to MIC
(12–13). At this time, the plasma binding of colistin in critically
ill patients is not known, because the concomitant presence of
variable concentrations of CMS in plasma samples and other
factors pose significant technical difficulties. Thus, the param-
eter estimates (effect in the absence of drug [Eo], maximal drug
effect [Emax], 50% effective concentration [EC50], and Hill co-
efficient) for the inhibitory sigmoid dose-effect model linking
the AUC0-24/MIC ratio (i.e., for the total plasma colistin con-
centration) with the magnitude of effect in the murine models
(unpublished data from references 12 and 13) were used in the
current translational analysis. Assuming similar plasma un-
bound fractions in mice and humans, it was possible to use the
human AUC0-24 values predicted using the maintenance dos-
ing algorithm, the respective MICs, and parameter estimates
from the murine models to predict the net logs of effect in the
murine models. The results of such an analysis for A. bauman-
nii in murine thigh infection are shown in Fig. 5; the graph
contains AUC0-24/MIC values for 105 critically ill patients  3
strains: 315 data points representing predicted logs of effect
relative to the respective baseline inocula. Results for similar
analyses performed for the same strains of A. baumannii in a
murine lung infection model (13) and for 3 strains of P. aerugi-
nosa studied in neutropenic mice with infected thighs and
lungs (12) are presented in Table 4. The number of cases
corresponding to various predicted magnitudes of effect
against each bacterial strain in each murine model is delin-
eated.
The potential consequences of commencing maintenance
therapy with CMS in the absence of a loading dose must be
considered. Because of slow conversion of the administered
prodrug, CMS, to the active antibacterial, colistin, and the long
half-life of the latter, accumulation to plasma colistin concen-
trations likely to be effective takes some time in the absence of
a loading dose (31). The slow accumulation of formed colistin
in plasma was also evident in the population PK model fits in
this study (Fig. 3). We used the fitted model to determine the
appropriate mean loading dose of CMS to more rapidly
achieve steady-state plasma concentrations of formed colistin.
A Monte Carlo simulation (ADAPT 5) (9) was performed,
simulating 9,999 randomly selected patients using parameters
and distributions achieved in our study. Equation 9 (Table 3)
represents the loading dose required to achieve a desired
plasma colistin Css,avg target; the loading dose should be cal-
culated using the lower of ideal or actual body weight and
would be administered on day one, followed by commence-
ment 24 h later of the relevant maintenance dosage regimen
(Table 3).
DISCUSSION
Data supporting dosing recommendations for CMS from
prospective studies continue to be scarce. Although some data
describing the PK of CMS and formed colistin in critically ill
patients are available (29, 31), the studies included only 14 and
18 patients, respectively, and all 32 patients had creatinine
clearance values greater than 40 ml/min; none of the patients
was in receipt of renal replacement therapy. Thus, the patient
populations were not representative of the full range of criti-
cally ill patients who may require intravenous administration of
CMS for treatment of a Gram-negative infection. Neither of
FIG. 5. Pharmacodynamic activity predicted by applying the
AUC0–24 values (from the algorithm-predicted maintenance doses tar-
geting a colistin Css,avg of 2.5 mg/liter) for each of the 105 critically ill
patients together with the PD parameters from 3 isolates of A. bau-
mannii in a murine thigh infection model (unpublished PD parameter
estimates referenced to total plasma colistin concentration from ref-
erence 13). The predicted logs of effect are relative to the respective
baseline inocula and are plotted as a function of creatinine clearance
in the critically ill patients. The symbols represent the following strains:
F, 248-01-C.248 (MIC  1.0 mg/liter); Œ, ATCC 19606 (MIC  1.0
mg/liter); and , N-16870.213 (MIC  0.5 mg/liter).
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these previous studies (29, 31) provided maintenance dosing
suggestions for CMS in critically ill patients. The current study
describes the disposition of the prodrug, CMS, and formed
colistin in 105 critically ill patients, including 12 on intermittent
hemodialysis and 4 on continuous renal replacement therapy.
Of the 105 patients, 69 had CrCL of less than 40 ml/min/1.73
m2. Based upon population PK analysis and a thorough search
for covariates in the disposition of CMS and formed colistin,
we have been able to develop dosing suggestions for various
categories of critically ill patients.
Across the two previous PK studies of critically ill patients
(29, 31), 30 patients received a CMS dose of 9 million units
(MU) per day, while the remaining two patients received 6 and
4 MU per day; this corresponds to a range of CBA doses of
about 120 to 270 mg/day, although clearly the majority of
patients received the highest dose. In the present study, there
was about a 5.5-fold range in the physician-selected daily dose
of CMS (75 to 410 mg CBA) across the patients, with a clear
trend for lower doses to be prescribed for patients with low
CrCL (Fig. 2A). There was an 	20-fold range in the AUC0–24
and corresponding Css,avg values for formed colistin (Fig. 2B;
see also Fig. 1B). Close examination of the data in both panels
of Fig. 2 is instructive. First, it reveals the important role of
renal function as a determinant of the plasma concentrations
of the active antibacterial, formed colistin; as discussed below,
CrCL was an important covariate in the population PK model
developed in this study. Second, it is evident that in patients
with moderate to good renal function, administration of a daily
dose of CBA at the upper limit of the current product-recom-
mended dose range (300 mg CBA per day) (2) was not able to
generate plasma colistin concentrations that would be ex-
pected to be reliably efficacious.
Our final (best-fit) population PK model was linear, with two
compartments for CMS and one compartment for colistin.
This structural model was similar to that used by Plachouras et
al. (31) to describe the disposition of CMS and formed colistin
in 18 critically ill patients; in the study by Markou et al. (29),
plasma concentrations of formed colistin only were quantified
in 14 patients and the resultant concentration-time profiles
were subjected to noncompartmental analysis. In the current
population PK analysis, the volume of the central compart-
ment for CMS was modeled as a function of weight and, as
discussed in more detail below, the clearances for CMS and
colistin were modeled as functions of CrCL. The volume of
distribution and clearance of formed colistin were conditioned
on fm, which in the current analysis represents the unknown
fraction of the nonrenal clearance of CMS resulting in forma-
tion of colistin. In the study by Plachouras et al. (31), the
reported clearance and volume of distribution for colistin were
conditioned on a different fm, the fraction of the total CMS
dose that was converted to colistin. The results from the cur-
rent and previous study agree well when we adjust the fm in
our study to mirror the one used by Plachouras et al. (31);
under these circumstances, in patients with CrCL values of at
least 40 ml/min/1.73 m2, the geometric mean apparent clear-
ance of colistin in our study was 10.8 liters/h with an intersub-
ject variability of 76.5%, compared to 9.09 liters/h with an
intersubject variability of 59% in the earlier study (31).
Renal function, expressed as CrCL, was an important cova-
riate for the clearance of both CMS and colistin in our popu-
lation PK model. In renally healthy individuals, the prodrug,
CMS, is predominantly cleared by renal excretion, with only a
relatively small fraction of a dose converted to the active an-
tibacterial, colistin (23, 26); thus, total clearance of CMS is
expected to decline with CrCL. At first thought it may seem
surprising that CrCL was an important covariate for the clear-
ance of formed colistin, because following direct administra-
tion of colistin in animal studies, it is cleared predominantly by
nonrenal mechanisms, with only a very small fraction of the
administered dose recovered in urine in unchanged form (24,
26). The explanation for CrCL being a covariate for the ap-
parent clearance of formed colistin in this study lies in the
somewhat unusual overall disposition of CMS and formed
colistin. As mentioned above, only a small fraction of an ad-
TABLE 4. Pharmacodynamic activity predicted by applying AUC0-24 values
a for each of 105 critically ill patients together with PD parameters
from 3 isolates of A. baumannii and 3 isolates of P. aeruginosa in murine thigh and lung infection modelsb
Study (reference) Strain MIC(mg/liter)
% of cases corresponding to predicted magnitude of effectc
 stasis Stasis to 1log kill
1 log kill to
2 log kill
2 log
kill
P. aeruginosa murine thigh infection (12) 19056 0.5 13.3 22.9 41.0 22.9
PAO1 1 78.1 17.1 1.9 2.9
ATCC 27853 1 95.2 1.9 0.0 2.9
P. aeruginosa murine lung infection (12) 19056 0.5 1.0 17.1 53.3 28.6
PAO1 1 36.2 52.4 8.6 2.9
ATCC 27853 1 24.8 62.9 9.5 2.9
A. baumannii murine thigh infection (13) 248-01-C.248 1 12.4 68.6 16.2 2.9
N-16870.213 0.5 7.6 11.4 22.9 58.1
ATCC 19606 1 0.0 21.9 75.2 2.9
A. baumannii murine lung infection (13) 248-01-C.248 1 18.1 62.9 16.2 2.9
N-16870.213 0.5 1.0 80.0 19.0 0.0
ATCC 19606 1 0.0 17.1 80.0 2.9
a AUC0-24 values are from algorithm-predicted maintenance doses targeting a colistin Css,avg of 2.5 mg/liter.
b Unpublished PD parameter estimates referenced to the total plasma colistin concentration from references 12 and 13.
c Percentage of cases (105 patients) corresponding to various predicted effects relative to the respective baseline inocula.
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ministered dose of CMS is converted to colistin (23); since
CMS is cleared predominantly by renal excretion, as CrCL
declines a progressively larger fraction of a dose of CMS will be
converted to colistin, although we cannot discount the possi-
bility of an associative decrease in the actual clearance of
colistin as renal function declines. The practical consequence
of this rather complex interplay of dispositional processes for
administered CMS and formed colistin and the impact of renal
function thereon are clearly evident in Fig. 2. Not surprisingly,
CrCL was the major PK factor involved in the CMS mainte-
nance dosing algorithm for generation of a target plasma con-
centration of formed colistin (Table 3, equation 10). Neither of
the previous PK studies of critically ill patients found CrCL to
be a covariate for the clearance of formed colistin (29, 31);
similarly, CrCL was not a covariate for the clearance of ad-
ministered CMS (31). It is very likely that the inability to detect
relationships between renal function and clearances of CMS
and colistin in the previous studies was the result of the small
sample sizes (14 and 18 patients) and the relatively narrow
range of CrCL values (40 ml/min) for the enrolled patients
(29, 31). We also found body size to be a relevant covariate
affecting the volume of the central compartment for CMS; as a
consequence, suggested CMS loading doses are a function of
body weight (Table 3). We did not, however, find any signifi-
cant trends in clearance of either CMS or colistin against body
size, and thus we were not able to propose a weight-based
maintenance dosing algorithm for CMS.
Since the physician-selected CMS maintenance doses in this
study provided a substantive variance in AUC0-24 (and corre-
sponding Css,avg) for colistin (Fig. 1), we developed a dosing
algorithm incorporating renal function to estimate the sug-
gested CMS maintenance dose (expressed as mg CBA per day)
required to reach a target Css,avg for colistin (Table 3, equation
10). CrCL as a covariate explained 	60% of the variability in
the “ideal” maintenance dose of CBA required to achieve a
given target Css,avg for colistin (Fig. 4). Further improving on
this precision would require identification of additional PK
covariates and/or development of an adaptive feedback control
algorithm for colistin (individual optimization based on PK/
PD/TD principles). The maintenance dosing algorithm per-
formed satisfactorily when it was applied to patients not on any
renal replacement and those on HD, using a colistin Css,avg
target of 2.5 mg/liter, corresponding to a steady-state colistin
AUC0-24 of 60 mg  h/liter. Similarly, the suggested CMS main-
tenance dose for patients on CRRT (Table 3) performed well
when applied to the 4 patients in this category.
It is noteworthy that the CMS maintenance dose required to
achieve each 1.0 mg/liter of the colistin Css,avg target in patients
on CRRT (192 mg CBA per day) (Table 3) is very similar to
that required in a patient with a CrCL of 	100 ml/min/1.73 m2
(Table 3, equation 10). This may seem surprising given that
colistin is predominantly nonrenally cleared in individuals with
normal kidney function (26). The explanation most likely re-
lates to the mechanisms involved in the renal handling of
colistin in the presence of intact kidney function in comparison
with the extracorporeal clearance mechanisms in operation in
CRRT. The renal handling of colistin involves very extensive
tubular reabsorption; this serves to retain in the body a very
large fraction of the filtered load of colistin, and it contributes
to an extremely low fraction excreted unchanged in urine (24,
26). In contrast, following clearance by diffusion and/or con-
vection in a CRRT cartridge, there is no carrier-mediated
mechanism to return colistin from dialysate to blood perfusing
the cartridge.
This and other (15, 28) studies have also shown that CMS
and colistin are efficiently cleared during intermittent HD; the
magnitudes of extracorporeal clearances of CMS and colistin
in this study are in accord with those reported elsewhere (15,
28). Even when a dialysis session occurs toward the end of a
CMS dosage interval, a substantial amount of CMS and colis-
tin would be cleared, necessitating a supplemental dose of
CMS to maintain a colistin Css,avg similar to that occurring on
a nondialysis day; a larger supplemental dose would be re-
quired if administered during dialysis compared with dosage
after the session (Table 3). Because of the large fluctuations in
plasma CMS concentrations during a dosage interval (Fig. 1),
a much larger amount of CMS would be cleared if dialysis
occurs early in a dosage interval. For this reason, it is suggested
that dialysis is best conducted toward the end of a CMS dosage
interval.
It is important to provide caveats about the loading and
maintenance dose suggestions for CMS in Table 3. When com-
puting the absolute loading dose of CBA from the result of
applying equation 9 (Table 3), the lower of either the actual or
ideal body weight should be used. In addition, there is little
experience with using (single daily) doses of CMS greater than
the current upper limit in the product information (300 mg
CBA), and the potential impact of large loading doses of CMS
on renal function is not known. Thus, at this time we suggest
caution in the use of a loading dose greater than 300 mg CBA.
In relation to suggested maintenance doses, the algorithm (Ta-
ble 3, equation 10) predicts the need for increasingly high CMS
maintenance doses as CrCL increases, and dependent upon
the desired colistin Css,avg, this may generate suggested CMS
daily doses above the upper limit (300 mg CBA per day) in the
current product labeling (2). For example, if targeting a colistin
Css,avg of 2.5 mg/liter, a patient with a CrCL of 70 ml/min/1.73
m2 would require 337.5 mg CBA per day. In such patients (i.e.,
with moderate to good renal function), it is theoretically pos-
sible to use daily doses of CMS higher than 300 mg CBA per
day to generate a desired target colistin Css,avg similar to those
occurring with lower maintenance doses of CMS in patients
with poorer kidney function (Fig. 2). However, increasing the
daily dose of CBA beyond the current upper limit daily dose in
patients with relatively good renal function comes at the ex-
pense of presenting a larger mass of CMS to the kidneys, with
the potential for intrarenal conversion to colistin (23), which
may increase the possibility of nephrotoxicity. This is not an
insignificant risk given the rate of nephrotoxicity even with the
currently recommended CMS dosage regimen. In the present
study, of the 89 patients not on renal replacement, all but two
had been prescribed a CMS maintenance dose of 300 mg CBA
per day or less, and 43/89 (48%) had a rise in serum creatinine
of 50%, of which, for 27/43 (63%), levels remained elevated
at the end of the study; these findings are similar to those
reported for other studies (10, 16). Thus, care is needed in the
use of the maintenance dosing algorithm for patients with
moderate to good renal function and/or when it is desired to
target a relatively high colistin Css,avg target, circumstances
where the algorithm-suggested daily dose of CBA may be sub-
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stantially greater than 300 mg/day. At this time, we do not
recommend use of the algorithm for patients with CrCL of
70 ml/min/1.73 m2 unless it is appropriate to target a low
Css,avg of colistin.
The PK data for critically ill patients obtained in the current
study were integrated with PD data for A. baumannii and P.
aeruginosa in murine thigh and lung infection models (12–13).
In undertaking these translational analyses, because of the
absence of information on plasma binding of colistin in criti-
cally ill patients, we utilized PD parameter estimates for total
(i.e., unbound plus bound) colistin in plasma in the murine
models and linked them with the colistin Css,avg (i.e., total
plasma concentration) expected to be achieved in the individ-
ual critically ill patients from algorithm-predicted maintenance
doses targeting a colistin Css,avg of 2.5 mg/liter. This approach
assumes that the “average” unbound fraction in infected mice
is similar to that in infected humans. We chose a colistin Css,avg
of 2.5 mg/liter (corresponding to a target AUC0-24 of 60 mg  h/
liter) for two reasons: first, it was similar to the median Css,avg
of 2.36 mg/liter in the 105 patients with the physician-selected
maintenance doses of CMS; second, against 3 strains each of A.
baumannii and P. aeruginosa in murine thigh and lung infection
models, a ratio of AUC0-24 to MIC of 60 was generally asso-
ciated with an effect somewhere between stasis and 1-log kill,
with the exception of P. aeruginosa in thigh infection, where a
smaller effect was observed (unpublished data from references
12 and 13 for data based on the total plasma colistin concen-
tration). From the results of these analyses, it appears that the
above maintenance doses (and resultant colistin Css,avg) would
not be reliably effective against isolates with MICs greater than
0.5 mg/liter (Fig. 5 and Table 4). It is our opinion that in order
to achieve dosage regimens with a high probability of safety
and efficacy, it appears that colistin might best be used as part
of a highly active combination. This is especially likely to be the
case for patients with moderate to good renal function, for
whom, as discussed above, it is not possible to achieve colistin
Css,avg values that are likely to be reliably effective without
administration of maintenance doses of CMS which may in-
crease the risk of nephrotoxicity.
In conclusion, this is the first study to report the results of
population PK modeling for more than 100 critically ill pa-
tients with a diverse range of renal functions, including those
requiring intermittent hemodialysis or continuous renal re-
placement therapy. Our modeling revealed that creatinine
clearance was an important covariate in the clearance of both
CMS and formed colistin. As a result, we have developed the
first scientifically based dosing suggestions for CMS to gener-
ate a desired target steady-state plasma concentration of
formed colistin in various categories of critically ill patients.
Our current results suggest that because of the inability to
achieve adequate plasma concentrations of formed colistin
with CMS monotherapy, CMS/colistin might best be used as
part of a highly active combination, especially when treating an
infection caused by an organism with an MIC of 0.5 mg/liter
in a patient with a creatinine clearance of 70 ml/min/1.73 m2.
The loading and maintenance dosing suggestions reported
herein should be regarded as interim; they will be refined as we
complete recruitment to a total of 238 critically ill patients and
also model the pharmacodynamic and toxicodynamic end-
points.
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